相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Control of Human Viral Infections by Natural Killer Cells
Stephanie Jost et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in Lung transplantation
Bijan Ghassemieh et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2013)
Low-Dose Rapamycin Treatment Increases the Ability of Human Regulatory T Cells to Inhibit Transplant Arteriosclerosis In Vivo
J. Hester et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
CMV Late Phase-Induced mTOR Activation Is Essential for Efficient Virus Replication in Polarized Human Macrophages
M. Poglitsch et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Immune response to CMV in solid organ transplant recipients: current concepts and future directions
Richard R. Watkins et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Efficient Human Cytomegalovirus Reactivation Is Maturation Dependent in the Langerhans Dendritic Cell Lineage and Can Be Studied using a CD14+ Experimental Latency Model
Margaret M. Huang et al.
JOURNAL OF VIROLOGY (2012)
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Dudley W. Lamming et al.
SCIENCE (2012)
Inhibition of Inflammatory Interleukin-6 Activity via Extracellular Signal-Regulated Kinase-Mitogen-Activated Protein Kinase Signaling Antagonizes Human Cytomegalovirus Reactivation from Dendritic Cells
Matthew B. Reeves et al.
JOURNAL OF VIROLOGY (2011)
Human Cytomegalovirus Infection Maintains mTOR Activity and Its Perinuclear Localization during Amino Acid Deprivation
Amy J. Clippinger et al.
JOURNAL OF VIROLOGY (2011)
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Human cytomegalovirus immunity and immune evasion
Sarah E. Jackson et al.
VIRUS RESEARCH (2011)
mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS
Heth R. Turnquist et al.
BLOOD (2010)
Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication
Nathaniel J. Moorman et al.
JOURNAL OF VIROLOGY (2010)
Experimental human cytomegalovirus latency in CD14+ monocytes
Danna Hargett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Number of Peripheral Blood Regulatory T Cells and Lymphocyte Activation at 3 Months After Conversion to mTOR Inhibitor Therapy
D. San Segundo et al.
TRANSPLANTATION PROCEEDINGS (2010)
Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures
Alexander Rolle et al.
APMIS (2009)
Breaking Human Cytomegalovirus Major Immediate-Early Gene Silence by Vasoactive Intestinal Peptide Stimulation of the Protein Kinase A-CREB-TORC2 Signaling Cascade in Human Pluripotent Embryonal NTera2 Cells
Jinxiang Yuan et al.
JOURNAL OF VIROLOGY (2009)
mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes
Beate Vollenbroeker et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function
Amelia Barilli et al.
CARDIOVASCULAR RESEARCH (2008)
Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences
Christophe Legendre et al.
CLINICAL INFECTIOUS DISEASES (2008)
Cytomegalovirus reactivation in critically ill immunocompetent patients
Ajit P. Limaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: A pooled analysis of clinical trials
L. Demopoulos et al.
TRANSPLANTATION PROCEEDINGS (2008)
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
Francisco M. Marty et al.
BLOOD (2007)
Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death
Matthew B. Reeves et al.
SCIENCE (2007)
AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection
Sagar B. Kudchodkar et al.
JOURNAL OF VIROLOGY (2007)
Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor and rictor-containing complexes
Sagar B. Kudchodkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1β triggers reactivation of latent cytomegalovirus in immunocompetent mice
Charles H. Cook et al.
JOURNAL OF VIROLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death
CP Baines et al.
NATURE (2005)
Rotenone-induced caspase 9/3-independent and -dependent cell death in undifferentiated and differentiated human neural stem cells
J Li et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Pathogenesis and prenatal diagnosis of human cytomegalovirus infection
MG Revello et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens
S Chakrabarti et al.
BONE MARROW TRANSPLANTATION (2004)
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase
SB Kudchodkar et al.
JOURNAL OF VIROLOGY (2004)
Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megatile analysis
P Ljungman et al.
BLOOD (2003)
The most abundantly transcribed human cytomegalovirus gene (β2.7) is non-essential for growth in vitro
BP McSharry et al.
JOURNAL OF GENERAL VIROLOGY (2003)
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
JH Antin et al.
BLOOD (2003)
NF-κB -: A potential therapeutic target for inhibition of human cytomegalovirus (re)activation?
S Prösch et al.
BIOLOGICAL CHEMISTRY (2002)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery
DH Kim et al.
CELL (2002)
Risk factors for cytomegalovirus reactivation after CD6+T-cell-depleted allogeneic bone marrow transplantation
TS Lin et al.
TRANSPLANTATION (2002)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
S Chakrabarti et al.
BLOOD (2002)
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection
WG Nichols et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease
S Blankenberg et al.
CIRCULATION (2001)
分享论文
